---
figid: PMC10385692__pharmaceutics-15-01936-g001
figtitle: Application of substrate reduction therapy (SRT) and enzyme replacement
  therapy (ERT) on the metabolic pathway of glycosphingolipids
organisms:
- NA
organisms_ner:
- NA
pmcid: PMC10385692
filename: PMC10385692__pharmaceutics-15-01936-g001.jpg
figlink: /pmc/articles/PMC10385692/figure/F1
number: F1
caption: 'Application of substrate reduction therapy (SRT) and enzyme replacement
  therapy (ERT) on the metabolic pathway of glycosphingolipids. GCS: Glucosylceramide
  synthase. α-Gal A: α-Galactosidase A. Gb3S: Gb3 Synthase. FD: Fabry disease. Gb3:
  Globotriaosylceramide. Gb4: Globotetraosylceramide'
papertitle: Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid
  for Substrate Reduction Therapy in Fabry Disease
reftext: Marina Beraza-Millor, et al. Pharmaceutics. 2023 Jul;15(7).
year: '2023'
doi: 10.3390/pharmaceutics15071936
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords: substrate reduction therapy | solid lipid nanoparticles | siRNA | Fabry
  disease | Gb3 synthase | gold nanoparticles
automl_pathway: 0.9227504
figid_alias: PMC10385692__F1
figtype: Figure
redirect_from: /figures/PMC10385692__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10385692__pharmaceutics-15-01936-g001.html
  '@type': Dataset
  description: 'Application of substrate reduction therapy (SRT) and enzyme replacement
    therapy (ERT) on the metabolic pathway of glycosphingolipids. GCS: Glucosylceramide
    synthase. α-Gal A: α-Galactosidase A. Gb3S: Gb3 Synthase. FD: Fabry disease. Gb3:
    Globotriaosylceramide. Gb4: Globotetraosylceramide'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ceramide
  - Ceramide
  - mRNA
---
